Development & validation of a robust commercial solution for measuring residual kanamycin-resistant plasmid DNA

Cell & Gene Therapy Insights 2021; 7(6), 849


Published: 10 August 2021
Tania Chakrabarty

Watch the video or read the poster to learn:

  • Current regulatory guidance for residual plasmid DNA
  • Development and validation of a highly robust multiplexed qPCR assay for the quantitation of residual plasmid DNA carrying kanamycin resistance genes

Tania Chakrabarty is driven by a passion to improve human lives and precision medicine using cutting-edge research and new technologies. Dr Chakrabarty earned her PhD in Biophysics from the University of Illinois at Urbana-Champaign where she studied the structure-function relationship of the muscle protein myosin using fluorescence spectroscopy. Over the last decade, Dr Chakrabarty has led R&D organizations developing clinical diagnostics and RUO products at both large companies and smaller startups. She has earned several awards in her career and is an author of multiple patents. She currently leads the Pharma Analytics R&D team at Thermo Fisher Scientific, overseeing the development of quality and safety testing solutions for biopharmaceutical products